Search Results
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
monotherapy and in combination with chemotherapy, with no dose-limiting toxicities observed and the maximum tolerated dose not reached at doses up to 25.0 mg/kg.Executive CommentaryDr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "The selection for an oral presentation
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
and 40.0% at 1.8 mg/kg and 2.4 mg/kg, respectively, with corresponding DCRs of 86.7% and 90.0%. Median PFS (mPFS) was 6.97 months and 5.09 months, respectively, while median OS (mOS) was not yet reached in the 1.8 mg/kg cohort and was 14.72 months in the 2.4 mg/kg cohort. In the 1.8 mg/kg cohort, the incidence
More news about: Antengene Corporation Limited
May 27, 2026, 15:38 ET Midea Carrier abre inscrições para o Service Master, competição nacional que premia os melhores instaladores de ar-condicionado
produtos cada vez mais inovadores, eficientes, econômicos e sustentáveis. No Brasil, são três operações industriais (Canoas/RS, Manaus/AM e Pouso Alegre/MG) que adotam métodos de produção sustentáveis, garantindo o compromisso da empresa com a gestão responsável do negócio. Foto -
More news about: Midea
May 27, 2026, 09:00 ET Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions
Wegovy® (semaglutide) injection 2.4 mg, Wegovy® HD (semaglutide) injection 7.2 mg, Wegovy® (semaglutide) tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Ozempic® (semaglutide) tablets 4 mg or 9 mg.About CagriSemaCagriSema
More news about: NOVO NORDISK INC.
May 27, 2026, 09:00 ET OIKOS® Expands High-Protein Shake Lineup with New Flavors
category.Designed around emerging consumption moments and trends, Mocha Latte taps into the growing protein-plus coffee ("proffee") movement with 95mg of caffeine for morning energy and afternoon pick me ups, while Strawberry offers a refreshing, fruit-forward flavor option for everyday protein routines
More news about: Danone USA
May 27, 2026, 09:00 ET FIELDS GOOD LAUNCHES COOKIES WITH BENEFITS, BACKED BY $1.8M FROM FEMALE FOUNDERS FUND
deepen the richness in this soft-baked cookie, finished with a touch of sea salt. Made with brain-supporting ingredients including 3g of creatine and 250mg of clinically-studied Cognizin® citicoline, our Focus Cookie supports improved focus and attention.Sleep Cookie: Ditch the gummies
More news about: Fields Good
May 27, 2026, 09:00 ET C4 Energy® Turns Up Summer with New Pink Lemonade Limited-Time Flavor, Plus Two Retailer-Exclusive Seasonal Launches
https://bit.ly/C4Hawaii.Each 16 oz can of C4 Performance Energy delivers 200mg of caffeine, zero sugar, and the performance-driven energy C4 fans know and love.The launches are part of C4 Energy's broader summer platform,
More news about: Nutrabolt
May 27, 2026, 08:31 ET MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
without titration in a 2:1 randomization ratio. Of the nine subjects enrolled in the 48 mg cohort, six entered an optional four-week extension phase at the same dose.DA-1726 was generally well tolerated up to the 48 mg dose level, with no serious adverse events or treatment-related discontinuations observed.
More news about: MetaVia Inc.
May 27, 2026, 08:30 ET Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Summary: The abstract describes EVANGELINE (NCT05607004), an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg (Z)-endoxifen plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.
More news about: Atossa Therapeutics Inc
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
May 27, 2026, 07:30 ET Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TSHR-IgG1exceeding >80% over the 12-week study.Participants with Graves' overt hyperthyroidism,
More news about: Biohaven Ltd.
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
remained HBeAg positive.In Cohorts 1-3, functional cure was achieved in 2/19 (10.5%) and 3/18 (16.7%) participants from the elebsiran 200 mg or 100 mg + PEG-IFNα cohorts, respectively, compared with 1/18 (5.6%) in the PEG-IFNα cohort. In Cohort 4, functional cure was achieved in 8/31 (25.8%) participants,
More news about: Brii Biosciences Limited
May 27, 2026, 04:43 ET Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty
affected children. The current standard of care involves treatment with GnRH agonists to halt pubertal progression.About FP-001 42 mgFP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide
More news about: Foresee Pharmaceuticals Co., Ltd.
May 26, 2026, 13:37 ET New Study Conducted at Sheppard Pratt Finds Psilocybin-Assisted Therapy May Reduce Chronic Suicidal Ideation
major depressive disorder and chronic suicidal ideation who had failed at least two prior antidepressant treatments. Participants received a single 25-mg dose of COMP360 psilocybin within a structured therapeutic protocol that included preparation, supervised administration, and integration sessions. Researchers
More news about: Sheppard Pratt
May 26, 2026, 10:50 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
triglyceride levels ≥500 mg/dL (5.65 mmol/L) were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 43% of participants had fasting triglycerides ≥880 mg/dL (~10 mmol/L). Participants were randomised to receive 50 mg or 80 mg of olezarsen or placebo
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 10:46 ET New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia
triglyceride levels ≥500 mg/dL (5.65 mmol/L) were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 43% of participants had fasting triglycerides ≥880 mg/dL (~10 mmol/L). Participants were randomised to receive 50 mg or 80 mg of olezarsen or placebo
More news about: Swedish Orphan Biovitrum AB
May 26, 2026, 09:26 ET At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.UNLOXCYT (cosibelimab-ipdl) was approved at 1,200 mg Q3W because PK/PD modeling showed it provides similar overall exposure and PD-L1 receptor coverage as the trial regimen of 800 mg Q2W. Since checkpoint inhibitors
More news about: Sun Pharma
May 26, 2026, 09:00 ET Orsini to Serve as Contracted Specialty Pharmacy for Gilead's Hepcludex® (bulevirtide‑gmod)
leader in rare disease pharmacy solutions, announced today that it is the contracted specialty pharmacy for Gilead's Hepcludex® (bulevirtide‑gmod) 8.5 mg, a subcutaneous injection for the treatment of chronic hepatitis delta (HDV) infection in adults without cirrhosis or with compensated cirrhosis, which
More news about: Orsini
May 26, 2026, 08:00 ET Prescription cannabis telehealth platform launches in Colorado, with multi-state expansion planned
peer-reviewed study found that 54 percent of active CBD users take less than 50mg per day, while clinical research shows that efficacy requires a dose of 200 to 400mg. Cope Now is the first telehealth platform purpose-built to deliver a structured pathway for patients to receive
More news about: Kazmira Therapeutics
May 26, 2026, 08:00 ET Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors and last-line uricase therapy. Currently, no suitable second-line options
More news about: Crystalys Therapeutics
May 26, 2026, 08:00 ET Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
therapy. LYMPHIR was administered intravenously on Days 1–3 of each 21‑day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200 mg IV) on Day 1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression.The
More news about: Citius Oncology, Inc.
May 26, 2026, 07:30 ET Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
in the opakalim 75 mg once-daily treatment group vs. 47 days in the placebo group, representing a 3-fold prolongation.In an ongoing open-label extension (OLE) study in focal epilepsy, an updated data analysis shows 54% of patients with focal epilepsy on opakalim 75 mg once-daily achieved
More news about: Biohaven Ltd.
May 26, 2026, 02:27 ET Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
and chronic migraine.Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was observed for both 100 mg and 300 mg doses of eptinezumab as early as Day 1 post-infusion. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who
More news about: H. Lundbeck A/S
May 25, 2026, 10:00 ET Levantamento sobre hemofilia revela 'acesso a tratamentos inovadores' como principal necessidade não atendida entre pacientes, cuidadores e profissionais de saúde
(fitusirana sódica) Qfitlia® (fitusirana sódica) é uma terapia de redução de antitrombina com caneta pré-preenchida de 50 mg e frasco-ampola de 20mg7. Qfitlia® (fitusirana sódica) previne sangramentos e ajuda a reequilibrar a hemostasia, reduzindo a AT (antitrombina), uma proteína anticoagulante,
More news about: Sanofi
May 25, 2026, 08:45 ET A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
PCSK9 ranging from 51% to 88%, at the lowest 0.3 mg/kg dose to the highest 1.0 mg/kg dose, respectively. Corresponding mean reductions in LDL-C were 9% (0.3 mg/kg), 44% (0.45 mg/kg), 45% (0.6 mg/kg), 33% (0.7 mg/kg), 51% (0.8 mg/kg), and 62% (1.0 mg/kg). These reductions were sustained over time, with
More news about: Eli Lilly and Company